文献速递呼吸危重症与机械通气呼吸道感染

间充质干细胞治疗COVID-19相关中重度ARDS的随机试验

A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

该随机对照试验纳入需机械通气的中重度COVID-19相关ARDS患者,比较两次输注2×10^6细胞/kg异体间充质干细胞与安慰剂(模拟输注)的疗效。因预设的死亡率从40%降至23%的疗效目标难以实现,试验在第三次中期分析时提前终止(n=222/计划300)。30天死亡率细胞组37.5%(42/112)对对照组42.7%(47/110),差异无统计学意义(RR 0.88;95%CI 0.64-1.21;P=0.43);间充质干细胞安全但未改善30天生存或60天无呼吸机天数。

要点

  • 间充质干细胞未降低中重度COVID-19相关ARDS患者的30天死亡率。
  • 60天无呼吸机生存期在细胞组与对照组间无显著差异。
  • 间充质干细胞输注未出现输注相关毒性,30天严重不良事件与对照组相似。

核心结论

  • 间充质干细胞治疗虽安全,但未改善中重度COVID-19相关ARDS患者的30天生存或60天无呼吸机天数。

研究设计与样本

  • 随机对照试验,将机械通气的中重度COVID-19相关呼吸衰竭患者随机分配接受两次2×10^6细胞/kg异体间充质干细胞输注或模拟输注,均联合标准治疗。
  • 计划样本量300例,第三次中期分析时因预设死亡率降低目标难以实现而提前终止,实际纳入222例。

主要发现

  • 30天死亡率细胞组为37.5%(42/112),对照组为42.7%(47/110),相对风险0.88(95%CI 0.64-1.21;P=0.43)。
  • 60天内无呼吸机存活天数中位秩细胞组为117.3(四分位距60.0-169.5),对照组为102.0(四分位距54.0-162.5),未报告统计学显著性。
  • 30天ARDS缓解或改善细胞组为51/104(49.0%),对照组为46/106(43.4%),比值比1.36(95%CI 0.57-3.21)。
  • 无输注相关毒性,30天总体严重不良事件两组相似。

临床怎么用

  • 结果表明间充质干细胞不应作为中重度COVID-19相关ARDS的常规治疗推荐。
  • 临床决策仍需以标准治疗为基础,间充质干细胞仅可在研究背景下考虑。

局限性

  • 试验因预设疗效目标难以实现而提前终止,实际样本量222例低于计划的300例。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: There are limited therapeutic options for patients with coronavirus disease (COVID-19)-related acute respiratory distress syndrome with inflammation-mediated lung injury. Mesenchymal stromal cells offer promise as immunomodulatory agents. Objectives: Evaluation of efficacy and safety of allogeneic mesenchymal cells in mechanically-ventilated patients with moderate or severe COVID-19-induced respiratory failure. Methods: Patients were randomized to two infusions of 2 million cells/kg or sham infusions, in addition to the standard of care. We hypothesized that cell therapy would be superior to sham control for the primary endpoint of 30-day mortality. The key secondary endpoint was ventilator-free survival within 60 days, accounting for deaths and withdrawals in a ranked analysis. Measurements and Main Results: At the third interim analysis, the data and safety monitoring board recommended that the trial halt enrollment as the prespecified mortality reduction from 40% to 23% was unlikely to be achieved (n = 222 out of planned 300). Thirty-day mortality was 37.5% (42/112) in cell recipients versus 42.7% (47/110) in control patients (relative risk [RR], 0.88; 95% confidence interval, 0.64-1.21; P = 0.43). There were no significant differences in days alive off ventilation within 60 days (median rank, 117.3 [interquartile range, 60.0-169.5] in cell patients and 102.0 [interquartile range, 54.0-162.5] in control subjects; higher is better). Resolution or improvement of acute respiratory distress syndrome at 30 days was observed in 51/104 (49.0%) cell recipients and 46/106 (43.4%) control patients (odds ratio, 1.36; 95% confidence interval, 0.57-3.21). There were no infusion-related toxicities and overall serious adverse events over 30 days were similar. Conclusions: Mesenchymal cells, while safe, did not improve 30-day survival or 60-day ventilator-free days in patients with moderate and/or severe COVID-19-related acute respiratory distress syndrome.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Bowdish ME, Barkauskas CE, Overbey JR, et al. A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19. Am J Respir Crit Care Med. 2023. PMID: 36099435. doi:10.1164/rccm.202201-0157OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。